Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266057 | 0.86 | CYP1A2 (0.43) | CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL496494 | 0.84 | CYP1A2 (0.42) | CYP1A2CYP2D6 | |
| SCHEMBL12320902 | 0.80 | CYP1A2 (0.52) | CYP1A2CYP2D6 | |
| SCHEMBL21771660 | 0.77 | CYP1A2 (0.48) | CYP1A2CYP2D6 | |
| SCHEMBL707889 | 0.76 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL706895 | 0.76 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL708799 | 0.76 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL707888 | 0.76 | CYP1A2 (0.62) | CYP1A2CYP2D6 | |
| SCHEMBL1443233 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL5703512 | 0.74 | CYP1A2 (0.41) | CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2192924-B1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD (IL) | 2017-10-11 | — | — | EP | disclosed |
| US-20140256017-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD. (IL) | 2014-09-11 | — | — | US | disclosed |
| US-8742079-B2 | Saccharide-containing protein conjugates and uses thereof | PROTALIX LTD. (IL) | 2014-06-03 | — | — | US | disclosed |
| US-20110105379-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD. (IL) | 2011-05-05 | — | — | US | disclosed |
| EP-2192924-A2 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | Protalix Ltd. (IL) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009024977-A2 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | PROTALIX LTD. (IL) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256017-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | STT3B, STT3A, DDOST | CYP1A2 4465/4885CYP2D6 3015/4885 |
| US-20110105379-A1 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF | STT3B, STT3A, DDOST | CYP1A2 4465/4885CYP2D6 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.